OR WAIT null SECS
INC Research® and invivodata® a provider of patient reported outcomes (PRO) solutions and services for global clinical research, announced a partnership in which invivodata provides its ePRO solutions and services as a component of INC’s full service offering portfolio. The partnership has evolved from the execution of multiple international clinical trials in which INC Research and invivodata clinical service teams have delivered ePRO solutions and services to global biopharmaceutical customers.
The partnership is similar to a recent agreement between invivodata and Quintiles. Both partnerships are non-exclusive with invivodata as the preferred ePRO partner.
“We chose to partner with invivodata based on the integration of scientific and regulatory principles into their ePRO solution - elements critical in ensuring high patient compliance and reliable data,” said Alistair Macdonald, INC Research’s executive vice president, Strategic Development. “By leveraging our relationship with invivodata, we can continue to guide our customers through any regulatory changes that may affect their research decisions, especially in light of the recent publication of the FDA's final PRO Guidance.”
invivodata combines scientific and regulatory expertise with technology and proactive services that enable clinical trial sponsors to determine the effectiveness of new medical products and therapies.
“We’re eager to continue building on our long-term relationship with INC Research, and to help maximize the value they deliver to global biopharmaceutical organizations," said Doug Engfer, invivodata president and CEO.